Agilent Technologies announced that it has completed its previously announced acquisition of Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners.
Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group.
Biocare Medical is a global provider of clinical pathology solutions, with a focus on immunohistochemistry and molecular pathology. The company offers automated instrumentation, reagents, and multiplexing technologies used to advance cancer diagnostics and research.
Agilent said the acquisition represents a strategic expansion of its pathology portfolio and strengthens its ability to serve customers across clinical and research settings.
The company expects the transaction to be accretive to Agilent’s top-line growth rate, margin profile, and non-instrument revenue mix in the first year. Agilent also expects the acquisition to become accretive to earnings per share approximately 12 months after the close.
Agilent said the expected impact on its fiscal 2026 financial results will be provided as part of its third-quarter earnings release.
Agilent is a global provider of analytical and clinical laboratory technologies. The company generated $6.95 billion in revenue in fiscal year 2025 and has approximately 18,000 employees worldwide.
Barclays served as financial advisor to Agilent, Sullivan & Cromwell served as legal advisor, and Joele Frank served as strategic communications advisor.
Jefferies served as exclusive financial advisor to Biocare, Ropes & Gray served as legal advisor, and ICR Healthcare served as strategic communications advisor.
KEY QUOTES:
“We are pleased to complete our acquisition of Biocare, which represents a natural and strategic expansion of Agilent’s pathology portfolio and strengthens our ability to serve customers across clinical and research settings.”
“At Agilent, we remain focused on investing in areas where we see clear opportunities to enhance our capabilities, accelerate customer-centric innovation and create long-term value for our shareholders. With Biocare’s talented team and complementary portfolio now part of Agilent, we are well positioned to build on our momentum and further support the evolving needs of our customers and partners.”
Padraig McDonnell, President and CEO of Agilent
